Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI
BE Sands(Icahn School of Medicine at Mount Sinai), WJ Sandborn(Mayo Clinic in Arizona), H Zhang(Janssen (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Gert Van Assche(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Stephan R. Targan(Cedars-Sinai Medical Center), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Philippe Szapary(Cedars-Sinai Medical Center), CD O'Brien(Janssen (United States)), Ramesh Arasaradnam(University Hospital Coventry), Jewel Johanns(Johnson & Johnson (United States)), Rupert W. Leong(The University of Sydney)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k